Mad Hedge Biotech and Healthcare Letter January 13, 2026 Fiat Lux Featured Trade: (NOT BAD FOR SCRAPS) (AZN), (PFE)
Tag Archives: (AZN)
Everyone forgets that Pfizer (PFE) tried to buy AstraZeneca (AZN) for scraps back in 2014. The UK Parliament threw a fit, the deal died, and Wall Street moved on. Fast forward, AstraZeneca is worth double what Pfizer is. The press still treats it like a mid-tier pharma shop. Meanwhile, it’s running the table in oncology. […]
Mad Hedge Biotech and Healthcare Letter October 16, 2025 Fiat Lux Featured Trade: (THE LAZINESS PREMIUM) (GSK), (AZN), (ABBV), (PFE), (GILD)
I spent last Tuesday afternoon on a call with a fund manager who runs $3 billion and couldn’t explain to me why his team was avoiding GSK (GSK). Something about HIV competition and patent cliffs and the usual hand-waving you get from analysts who haven’t actually dug into the numbers. I let him finish his […]
Mad Hedge Biotech and Healthcare Letter March 20, 2025 Fiat Lux Featured Trade: (EVEN A PIG COULD MAKE MONEY HERE) (OGN), (MRK), (RHHBY), (BAYRY), (PFE), (AZN)
I was camped out in Kyiv the other month when news of Organon’s (OGN) earnings hit my phone. While Russian drones buzzed overhead, I was studying pharmaceutical balance sheets—talk about surreal. Did I mention I’ve led a strange life? In mid-February, Organon pleasantly surprised me with Q4 2024 results. Hadlima, their biosimilar to Humira, rocketed […]